• Description
  • Programmes
  • Contact

Sectors: Health, Research

Beneficiaries: Corporations, Research centres

Regions: European Union

Category: Call for proposals


To view this information, please connect.

Responsible: European commission


To view this information, please connect.


To view this information, please connect.


To view this information, please connect.


This call for proposals aims to develop a translational research project for the induction and monitoring of immune tolerance in rheumatoid arthritis.

Priorities and funded actions:

Work package 1: Management, coordination, dissemination and sustainability
– Overall coordination of the scientific work packages, budgets, delivery and dissemination of findings and sustainability planning.
Work package 2: Technologies for monitoring immune state.
– Deep immunophenotyping of patient samples using state of the art technologies such as T cell specificity using tetramers, autoantibody profiling and others.
Work package 3: Patients, cohorts and ethics
– Analysis of retrospective and design and prosecution of prospective clinical trials.
Work package 4: Mechanisms of immune tolerance – basic research
– Detailed analysis of patient tissues and samples to identify novel targets and pathways relevant to immune tolerance.
Work package 5: Bioinformatics and data
– Integration of historic and prospective data for the identification of biomarkers, stratification of patient cohorts and potentially new clinical targets. 

Among financed actions
– Development of ‘companion diagnostics’ that make it possible to recognise specific immune reactions in different subsets of patients with RA and other relevant inflammatory disease including lupus and myositis. 
– Development of tools for immuno-monitoring of T and B cell numbers and phenotype, as well as for other relevant immune and non-immune cell types. These tools should enable the evaluation of immunological effects of potential tolerance-inducing therapies. 
– Identification of relevant RA patient cohorts that would be suitable for testing ‘tolerising’ therapies. Patient selection could be based on genetics, response to therapy, immune phenotype and auto-antibody profiles for example. 
– Conduct experimental medicine studies using a small number of carefully selected RA patients to monitor changes in immunity following therapeutic intervention.